1. Home
  2. BXC vs VSTM Comparison

BXC vs VSTM Comparison

Compare BXC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

HOLD

Current Price

$56.09

Market Cap

587.2M

ML Signal

HOLD

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$5.31

Market Cap

470.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXC
VSTM
Founded
2004
2010
Country
United States
United States
Employees
1700
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
587.2M
470.7M
IPO Year
2004
2011

Fundamental Metrics

Financial Performance
Metric
BXC
VSTM
Price
$56.09
$5.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$86.00
$16.50
AVG Volume (30 Days)
93.6K
2.1M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.49
EPS
0.02
N/A
Revenue
N/A
$30,914,000.00
Revenue This Year
$5.04
$282.64
Revenue Next Year
$5.09
$72.25
P/E Ratio
$2,801.50
N/A
Revenue Growth
N/A
209.14
52 Week Low
$44.78
$4.01
52 Week High
$88.30
$11.25

Technical Indicators

Market Signals
Indicator
BXC
VSTM
Relative Strength Index (RSI) 51.73 44.56
Support Level $52.71 $4.80
Resistance Level $66.64 $6.79
Average True Range (ATR) 2.44 0.38
MACD 1.21 0.05
Stochastic Oscillator 87.21 47.89

Price Performance

Historical Comparison
BXC
VSTM

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: